{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:45:16Z","timestamp":1777927516696,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Background: In this service evaluation we evaluate the usage of emtricitabine and tenofovir alafenamide (FTC-TAF) in a large Scottish sexual health service providing Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP) over a one-year period (May 2022-May 2023).<\/jats:p>\n                  <jats:p>Purpose: We evaluated the use of FTC-TAF as it is 30 times more expensive per 30 tablet supply than emtricitabine\/tenofovir disoproxil (FTC-TDF). We sought to establish: - Number of patients initiated on FTC-TAF - Reasons for FTC-TAF initiation - Adherence to FTC-TAF.<\/jats:p>\n                  <jats:p>Results: Out of a total cohort of 1744 patients on HIV PrEP as of May 2023, seven patients (0.4%) had been initiated on FTC-TAF. The remainder (99.6%) were taking FTC-TDF. The majority of patients ( n = 6) were initiated on FTC-TAF due to renal reasons, one patient was initiated FTC-TAF for bone mineral density concerns.<\/jats:p>\n                  <jats:p>Conclusions: All of the patients met eligibility criteria. In terms of adherence, three patients were regular attenders, two patients used FTC-TAF sporadically, and two had initiated and subsequently discontinued FTC-TAF altogether at the time of data analysis. FTC-TAF utilisation was lower than anticipated, initiated apropriately, and followed similar adherence patterns to FTC-TDF users. This will be helpful for financial forecasting and in the development of services where FTC-TAF is newly commissioned.<\/jats:p>","DOI":"10.1177\/09564624231220098","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:47:26Z","timestamp":1701823646000},"page":"308-310","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emtricitabine\/tenofovir alafenamide usage in a Scottish sexual health service providing HIV pre-exposure prophylaxis: A service evaluation"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4249-7771","authenticated-orcid":false,"given":"Nathan","family":"Burley","sequence":"first","affiliation":[{"name":"Sandyford Sexual Health Services, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Sandyford Sexual Health Services, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aafreen","family":"Khan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"bibr1-09564624231220098","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30078-4"},{"key":"bibr2-09564624231220098","volume-title":"Emtricitabine\/Tenofovir disoproxil Mylan 200mg\/245mg film coated tablets","author":"Electronic Medicines Compendium","year":"2018"},{"key":"bibr3-09564624231220098","unstructured":"Electronic Medicines Compendium. Summary of product characteristics.\n                      Descovy 200mg\/25mg film coated tablets\n                      . [internet]. London: EMC; 2016 [updated 2023 May 26; cited 2023 Aug 14]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2108\/smpc"},{"key":"bibr4-09564624231220098","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"bibr5-09564624231220098","volume-title":"Eligibility criteria for tenofovir AF\/emtricitabine (Descovy\u00ae) for pre-exposure prophylaxis for HIV (PrEP) in Scotland","author":"Public Health Scotland","year":"2022"},{"key":"bibr6-09564624231220098","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2021-055277"},{"key":"bibr7-09564624231220098","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231220098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624231220098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231220098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:45:16Z","timestamp":1777675516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624231220098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1177\/09564624231220098"],"URL":"https:\/\/doi.org\/10.1177\/09564624231220098","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}